Lumateperone shows rapid benefit in bipolar mania

Clinical takeaway: Lumateperone is not approved for acute mania, but two positive phase 3 trials suggest a potential additional option for adults with bipolar I disorder.

Acute mania has several effective treatments, but differences in response and tolerability can complicate medication selection. Caplyta (lumateperone) already approved for bipolar depression, could add another option with evidence across both depressive and manic episodes if the new indication is approved.

By week 3, 43.9% of lumateperone recipients achieved at least a 50% reduction in manic symptoms, compared with 23.7% receiving placebo. This represents about 20 additional responders per 100 patients treated.

Average symptom scores improved compared with placebo as early as day 3, with benefits maintained through the 3-week trial. Overall illness severity also improved.

Dizziness occurred in 10.4% of lumateperone recipients versus 1.7% with placebo; dry mouth and somnolence were also more common with treatment. Discontinuation because of adverse events occurred in 4.0% versus 3.4%.

The global, randomized, double-blind phase 3 trial treated 351 adults hospitalized for a manic episode associated with bipolar I disorder, with or without mixed features. Participants received once-daily lumateperone 42 mg or placebo for 3 weeks. Baseline symptom scores indicated severe mania.

Johnson & Johnson plans to use findings from both positive phase 3 trials to support a US regulatory submission for bipolar mania.

“Manic episodes can disrupt a person’s safety, relationships, and daily life within days, underscoring the need for treatments that act rapidly,” said Jane Tiller, FRCPsych, vice president and global head of development, neuroscience, at Johnson & Johnson.

Sources: Johnson & Johnson. (2026 Nov 10). Johnson & Johnson announces CAPLYTA (lumateperone) shows significant and rapid improvement in bipolar mania in second pivotal phase 3 study; McIntyre RS, et al. (2026 Nov 5–8). NEI Fall Congress. Poster 98. Lumateperone for the treatment of bipolar mania in patients with bipolar I disorder: results from a double-blind, placebo-controlled, randomized, Phase 3 trial